Related Experiment Videos
Growth factors and oncogenes in pancreatic cancer
Abstract:
There are abnormalities in the structure and/or function of several oncogenes and growth factors in human pancreatic cancer, notably the EGF receptor and its ligand TGF alpha, c-erb B-2 proto-oncogene, Ki-ras oncogene and the tumour suppressor gene p53. The temporal sequence of their activation and the nature of the aetiological agents responsible for their activation are not yet clear. In vitro pancreatic culture systems and transgenic animal experiments are needed to reconstruct and define those molecular events that are necessary and sufficient for the neoplastic phenotype.
Insights
Human pancreatic cancer involves abnormalities in oncogenes and growth factors like EGF receptor and p53. Further research using in vitro and animal models is needed to understand the molecular events driving cancer development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human pancreatic cancer exhibits structural and functional abnormalities in key oncogenes and growth factors.
- Specific genes implicated include the EGF receptor, TGF alpha, c-erb B-2 proto-oncogene, Ki-ras oncogene, and the p53 tumor suppressor gene.
Purpose of the Study:
- To investigate the molecular underpinnings of human pancreatic cancer.
- To clarify the temporal sequence and etiological agents responsible for the activation of specific oncogenes and growth factors.
Main Methods:
- Review and analysis of existing data on oncogene and growth factor abnormalities in pancreatic cancer.
- Identification of knowledge gaps regarding the activation pathways and causative agents.
Main Results:
- Confirmed involvement of multiple oncogenes (e.g., Ki-ras, c-erb B-2) and growth factors (e.g., EGF receptor, TGF alpha) in pancreatic cancer.
- Highlighted the critical role of the p53 tumor suppressor gene.
Conclusions:
- The precise timing and causes of oncogene/growth factor activation in pancreatic cancer remain unclear.
- In vitro pancreatic culture systems and transgenic animal models are essential for defining the molecular events leading to the neoplastic phenotype.